Objective-Since March 1992, intravenous nalbuphine hydrochloride has been used prehospital by paramedics in the Plymouth area. This study assesses the impact of this intervention. Methods-A prospective study of the parenteral analgesic requirements of 1000 consecutive patients arriving by ambulance at the accident and emergency (A&E) department of a large district general hospital. Where parenteral analgesia was given in the A&E department but not by ambulance personnel, a questionnaire was sent to the ambulance crew concerned to ascertain the reasons for not having given nalbuphine. Results-Of 1000 consecutive patients arriving by ambulance, 87 (8.7%) had been given parenteral analgesia either prehospital, in A&E, or in both places.. Seventy five (7.5%) needed parenteral analgesia in the A&E department, 29 (2.9%) had been given prehospital intravenous analgesia by paramedics, and a further seven (0.7%)
had been given parenteral analgesia by a general practitioner (GP). Thus 36 (3.6%) received prehospital analgesia. Ten patients who had been given analgesia by paramedics required no further analgesia in A&E, whereas 51 patients who had not been given prehospital analgesia required parenteral analgesia in the A&E department.
Conclusions-The introduction of nalbuphine for use by paramedics in prehospital care has increased prehospital parenteral analgesia from 1% in 1992 (given by GPs only) to 3 .6% in the current study group, and 41% of patients requiring parenteral analgesia received analgesia prehospital. There may be further scope for extending the The maximum dose in the guidelines has since been reduced to 20 mg, but this can be exceeded following radio consultation with an experienced A&E doctor. A survey3 set in our accident and emergency (A&E) department in 1991 before the introduction of nalbuphine use by paramedics showed that 69 patients from a series of 502 ambulance patients (14%) received opiate analgesia in the A&E department. Unpublished data from the same study showed that 1% of ambulance patients had been given prehospital analgesia by a general practitioner. Since then paramedics throughout the Westcountry Ambulance Service Trust have been giving nalbuphine prehospital and our present study assesses the impact this has had on patient care.
Methods
We analysed the parenteral analgesic requirement of 1000 consecutive patients arriving by ambulance at the A&E department of a large district general hospital (approximately 67 000 new attendances per year) with a mixed urban and rural catchment area. A list of the previous days' ambulance attendances was generated on a daily basis from the A&E administration computer and the ambulance report forms and casualty cards were retrieved. A proforma was completed for each patient arriving by ambulance who had received parenteral analgesia, either prehospital or in A&E, and the data were entered onto a spreadsheet. Patients who had not had parenteral analgesia were merely counted and the study was terminated at 27 days when the 1 000th consecutive ambulance arrival was reached.
In cases where parenteral analgesia had been given in the A&E department but not by the Ten patients who had been given nalbuphine by paramedics did not require further parenteral analgesia in the A&E department. Nineteen patients required further analgesia in A&E. Thus over one third of patients given analgesia by paramedics needed no further analgesia in the A&E department. Table 1 shows the range of presenting complaints in these two groups. The list includes dislocations and soft tissue injuries which may be difficult to differentiate in the field from fractures, and a small number of conditions where nalbuphine was given outside the protocol following consultation with a senior A&E doctor.
In the A&E department, 75 patients (7.5%) were given parenteral analgesia and 51 of these had not received prehospital analgesia. The most commonly used preparation was morphine (51 patients), with 10 patients receiving diamorphine, nine receiving pethidine, and Chambers and Guly.3 Unpublished data from that study based in the same A&E department showed that before the introduction of nalbuphine for use by paramedics, five patients out of 502 consecutive ambulance arrivals (1 %) had received prehospital analgesia (invariably given by a general practitioner) and 69 (14%) had been given analgesia in A&E. The increase from 5/502 to 36/1000 in patients receiving prehospital analgesia is statistically significant (y2 = 8.5352, p = 0.003). This change meant that 41% of patients requiring parenteral analgesia received it prehospital by paramedics.
We were surprised that the requirement for parenteral analgesia has decreased since 1991 (8.7% v 14%) at a time when there has been an increased emphasis on the need for adequate and timely analgesia. The decrease from If the administration of parenteral analgesia by doctors in the A&E department is taken as defining those patients who need analgesia, there has been an increase in the proportion given analgesia prehospital from five of 69 (7.25%) in 1991 to 36 of 87 (41%) in the current study. Table 3 shows that there may be scope for further improvement if the indications for nalbuphine were extended (13 fell outside the protocol) and all paramedic crews were fully trained to give nalbuphine (three were not qualified to give nalbuphine).
Sixty seven per cent of patients given prehospital analgesia required further parenteral analgesia in the A&E department. This was not entirely unexpected, as repeat doses of analgesia would often be given for many of the conditions encountered. Fourteen patients who received the maximum dose of 20 mg required further analgesia in the A&E department. These figures suggest that more patients might benefit from nalbuphine and a maximum dose of 30 mg rather than 20 mg might be more appropriate. Since completion of this study, doses of 30 mg have been given on several occasions by paramedics without any complications, following telephone consultation with a senior A&E doctor. Paramedics have been fully trained in the use of naloxone for reversal of respiratory depression caused by nalbuphine. Any increased use of nalbuphine must also be balanced against the increased on-scene time, with other implications on patient care. 4 The questionnaire highlighted various points. Not all ambulance staff are currently qualified to give nalbuphine. Patients may not initially complain of pain to the ambulance personnel or may refuse opioids and opt for entonox, which may provide sufficient analgesia. Nalbuphine is currently given for a relatively narrow spectrum of conditions, and contraindications for its use featured prominently in the reasons for not giving it. There may be scope for extending its use for non-traumatic conditions such as back pain, renal colic, and abdominal pain after telephone advice from an experienced A&E doctor, and also in a few stable patients with more than one injury.
